BioMarin's Quiet Growth vs Market Surge | Business and Finance News

BioMarin’s stock has quietly gained 6.5% over six months, lagging the S&P 500’s 11% surge, as investors eye its shaky operating margins and weak ROIC—just 2.7% over five years, below the cost of capital for healthcare firms. While the stock isn’t overpriced at 10.5x forward earnings, the fundamentals aren’t compelling enough to justify a buy. Instead, the podcast suggests looking toward endpoint security firms, where AI-driven growth and stronger capital efficiency are creating more attractive opportunities. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/c296c90bbad53d3d